Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
|Articles|February 17, 2011
A Review of Systems That Covers All the Bases
Here is a tip that can help you cover all the elements of the review of systems: Ask the question as you examine the relevant body part.
Advertisement
Here’s a tip that can help you cover all the elements of the review of systems: Ask the question as you examine the relevant body part. For example, ask the patient, “Any trouble with your hearing?” as you look in the ears and, “When did you last see the dentist?” as you examine the mouth.
-Hugh Silk, MD
Worcester, Mass
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
Advertisement
Advertisement
Trending on Patient Care Online
1
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
2
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
3
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
4
FDA Approves Insulin Efsitora Alfa-Gobe for Adults With Type 2 Diabetes
5